NTA fell 10.7% to $1.58 as portfolio return swung to -3.5%

The shape sits entirely in the second half: H1 NPAT of $56.9m was more than reversed by an implied H2 loss of approximately $74.2m, producing a full-year net loss of $17.3m versus a $142.7m profit in FY21.

Active return collapsed to +0.1pp over the -3.6% benchmark, against +12.9pp in FY21, so the headline weakness reflects market drawdown more than poor relative performance. Net assets attributable contracted 8.3% to $505.4m. Investment income from dividends and interest, which excludes fair-value movements, rose 44.4% to $7.9m. The full-year distribution lifted to 14.34cps (+6.4%), although the final-quarter component fell to 3.16cps from 3.6cps.

The manager beat its benchmark by just 0.1pp this year, against 12.9pp in FY21. The company's value proposition rests on active stock selection; one year of benchmark-matching is not thesis-breaking, but it removes a historical differentiator and warrants attention if it persists.

Distributions are growing while NTA is shrinking. Full-year distributions rose 6.4% to 14.34cps even as NTA per share fell 10.7%. Prior-year distribution coverage was already only 25.4% of NPAT, and the current loss removes earnings coverage entirely, so payments are being funded from accumulated capital. That is consistent with the investment-company structure but accelerates NAV erosion in a drawdown year.

Cash income from the portfolio strengthened. Dividend and interest receipts of $7.9m (+44.4%) show the underlying holdings continued to generate growing distributable income. The $17.3m loss is a mark-to-market outcome, not an erosion of the recurring income stream that ultimately backs distributions.

The release frames FY22 as a year of two halves, with gains through 30 September 2021 reversing as markets weakened into March 2022. Total shareholder return for the year was +0.02%, essentially flat, despite the reported NPAT loss.

The HY22 result of $56.9m NPAT and $63.2m revenue, set against the FY22 outcome, implies the second half delivered approximately -$74.2m NPAT and -$73.8m of investment return, so the reversal accelerated rather than stabilised through the period. Without forward guidance the release does not support a view on FY23 trajectory; it does establish that the H2 weakness is fully captured in the closing NTA of $1.58.

Dividend and interest income rose 44.4% to $7.9m, indicating that the underlying portfolio's distributable income strengthened even as marks fell. That distinction matters: the $17.3m net loss is portfolio remeasurement, not impairment of recurring income.

Capital position remains constructive in a multi-year context. NTA per share at $1.58 still sits at the upper edge of Annolyse's historical baseline (mean $1.47, range $1.34-$1.77), and net assets of $505.4m sit above the historical mean of $485.1m. The balance sheet carries no borrowings, with cash of $8.0m down from $33.5m as positions were redeployed into the portfolio. ROE of -3.4% is at the lower edge of the historical range (mean 8.7%); that is mechanically expected given a loss year and should not be extrapolated forward.

This briefing cannot assess forward portfolio positioning or whether the March 2022 NTA marked a cyclical low for the underlying holdings.